Home › Funds › Atle Fund Management AB › BCAX

Atle Fund Management AB position in BCAX

BICARA THERAPEUTICS INC · Health Care

Atle Fund Management AB reported holding 145,657 shares of BCAX (BICARA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$4.3M, representing 1.16% of its reported portfolio and ranking #33 among its reported holdings. Atle Fund Management AB has disclosed BCAX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)145.66K sh
Reported value held$4.32M
Portfolio Weight1.16%
First reportedQ1 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Atle Fund Management AB's BCAX position evolved

Atle Fund Management AB first disclosed a stake in BCAX in Q1 2025 at 119,833 shares (US$1.6M). The position peaked in Q2 2026 at 145,657 shares, worth US$4.3M. Across 6 filings, Atle Fund Management AB increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 145,657 shares valued at US$4.3M — a reduction of -1,023,977 shares quarter over quarter.. Notable position changes include a 45% trim in Q4 2025 (shares rose 18% over the following quarter), a 950% increase in Q1 2026 (shares rose 49% over the following quarter), a 88% trim in Q2 2026 (shares fell 37% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 119.83K $1.56M New
Q2 2025 147.38K $1.37M Add
Q3 2025 203.75K $341.56K Add
Q4 2025 111.36K $1.87M Reduce
Q1 2026 1.17M $2.32M Add
Q2 2026 145.66K $4.32M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCAX and 13F data

BCAX (BICARA THERAPEUTICS INC) is a Health Care company. 58 other funds we track also report a position in BCAX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$215.4M), Siren, L.L.C. (US$166.4M), Vestal Point Capital, LP (US$155.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCAX

All BCAX fund holders →

FAQ

How long has Atle Fund Management AB held BCAX?

Atle Fund Management AB has disclosed BCAX holdings in 6 of the last 6 reported quarters, going back to Q1 2025.

What is Atle Fund Management AB's current position in BCAX?

As of Q2 2026, Atle Fund Management AB holds 145.66K shares of BCAX (BICARA THERAPEUTICS INC), valued at $4.32M, representing 1.16% of its reported portfolio and ranking #33.

Has Atle Fund Management AB been buying or selling BCAX?

In the latest 13F filing (Q2 2026), Atle Fund Management AB reduced its position in BCAX. The position peaked in Q2 2026 at 145.66K shares.

Which other funds hold BCAX?

Other major institutional holders of BCAX include RA CAPITAL MANAGEMENT, L.P., Siren, L.L.C., Vestal Point Capital, LP, among 58 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.